Tina J. Hieken, MD, on Treatment Advances in High-Risk Regionally Advanced Melanoma: Clinical Implications

Posted: Monday, April 1, 2024

Tina J. Hieken, MD, of the Mayo Clinic School of Graduate Medical Education, discusses the treatment landscape for patients with high-risk surgically resectable stage III melanoma and explores topics including neoadiuvant immunotherapy, who should still receive adjuvant treatment, and whether it's beneficial to de-escalate adjuvant systemic therapy or the extent of surgery based on pathologic response.

---